Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Conditions
Interventions
PIT565
Locations
13
Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Budapest, Hungary
Start Date
October 8, 2024
Primary Completion Date
July 9, 2027
Completion Date
July 9, 2027
Last Updated
March 23, 2026
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions